Format

Send to

Choose Destination
See comment in PubMed Commons below
Biologics. 2007 Jun;1(2):113-20.

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma.

Author information

1
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA.

Abstract

With the success of targeted monoclonal antibody therapy in non-Hodgkin's lymphoma, attempts were made to further improve efficacy through the addition of a radioisotope. A goal of radioimmunotherapy is to utilize the monoclonal antibody to deliver radiation to a tumor bed with relatively limited toxicity to the surrounding normal tissues. I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin's lymphoma (NHL). For more than a decade now, radiolabeled tositumomab has principally been evaluated in low-grade and transformed low-grade NHL patients with proven efficacy in both the up-front and salvage settings. Studies have included its use as a single agent, in combination with chemotherapy and as part of a conditioning regimen for autologous stem cell transplantation. These data suggest that this agent has an important role in the treatment of patients with B cell lymphoma.

KEYWORDS:

B-cell lymphoma; iodine-131-labeled tositumomab; non-Hodgkin’s lymphoma; tositumomab

PMID:
19707321
PMCID:
PMC2721297
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center